Imipenem/relebactam pharmacokinetics in critically ill patients supported on extracorporeal membrane oxygenation.
Andrew J FratoniAbigail K KoisJason A GluckDavid P NicolauJoseph L KutiPublished in: The Journal of antimicrobial chemotherapy (2024)
Imipenem/cilastatin/relebactam dosed according to package insert in patients supported on ECMO is predicted to achieve exposures sufficient to treat susceptible Gram-negative isolates, including Pseudomonas aeruginosa.
Keyphrases
- extracorporeal membrane oxygenation
- gram negative
- acute respiratory distress syndrome
- pseudomonas aeruginosa
- multidrug resistant
- end stage renal disease
- respiratory failure
- newly diagnosed
- ejection fraction
- chronic kidney disease
- cystic fibrosis
- prognostic factors
- acinetobacter baumannii
- air pollution
- drug resistant
- intensive care unit
- biofilm formation
- patient reported outcomes
- staphylococcus aureus
- escherichia coli
- genetic diversity